Herman Miller (MLHR) Tops Q4 EPS by 21c

Herman Miller (NASDAQ: MLHR) reported Q4 EPS of $0.11, $0.21 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $475.7 million versus the consensus estimate of $479.63 million.

with the Securities and Exchange Commission.

First Quarter Fiscal 2021 Guidance

The outbreak of COVID-19 has created a high degree of uncertainty throughout the global economy. Due to this uncertainty, and the rapidly changing effects of risk mitigation efforts to control the outbreak around the world, we are not able to reasonably estimate the impact of the outbreak on our business or financial results in the near-term. Accordingly, we are continuing to withhold providing guidance for the upcoming quarter while this uncertainty persists.

For earnings history and earnings-related data on Herman Miller (MLHR) click here.

You May Also Be Interested In

• FDA grants accelerated approval to Bristol Myers Squibb's Zenbexus
• Innovaro (INV) Misses Q2 EPS by 9c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c